{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:10:13Z","timestamp":1791234613066,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007525","name":"University of Rennes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104675","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:43:00Z","timestamp":1776728580000},"page":"104675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Usefulness of the sulfonamide motif in medicinal chemistry: exploring the pharmacological landscape of FDA-approved and investigational sulfonamide drugs"],"prefix":"10.1016","volume":"31","author":[{"given":"S\u00e9bastien","family":"Sueron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Vigroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Hugues","family":"Por\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104675_b0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/prac.19080770129","article-title":"\u00dcber sulfamide der p\u2010amidobenzolsulfons\u00e4ure","volume":"77","author":"Gelmo","year":"1908","journal-title":"J F\u00fcr Prakt Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202403434","article-title":"Sulfonamides as a promising scaffold in drug discovery: an insightful review on FDA\u2010approved molecules, synthesis strategy, medical indication, and their binding mode","volume":"22","author":"Aslam","year":"2025","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.drudis.2026.104675_b0015","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1021\/acs.jmedchem.0c00754","article-title":"The most common functional groups in bioactive molecules and how their popularity has evolved over time","volume":"63","author":"Ertl","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1021\/acs.jnatprod.7b00921","article-title":"Natural products containing a nitrogen\u2013sulfur bond","volume":"81","author":"Petkowski","year":"2018","journal-title":"J Nat Prod"},{"key":"10.1016\/j.drudis.2026.104675_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117194","article-title":"The most common linkers in bioactive molecules and their bioisosteric replacement network","volume":"81","author":"Ertl","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2016.09.091","article-title":"Sulfoximines from a medicinal chemist\u2019s perspective: physicochemical and in vitro parameters relevant for drug discovery","volume":"126","author":"Frings","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0035","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1039\/C8QO01233D","article-title":"Neglected sulfur(vi) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development","volume":"6","author":"L\u00fccking","year":"2019","journal-title":"Org Chem Front"},{"key":"10.1016\/j.drudis.2026.104675_b0040","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17460441.2021.1948008","article-title":"How do we address neglected sulfur pharmacophores in drug discovery?","volume":"16","author":"Tilby","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2026.104675_b0045","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17460441.2022.2044783","article-title":"The importance of sulfur-containing motifs in drug design and discovery","volume":"17","author":"Mustafa","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2026.104675_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/ci7002494","article-title":"Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis","volume":"48","author":"Brameld","year":"2008","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2026.104675_b0055","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.bmcl.2007.02.034","article-title":"Sulfonamide-related conformational effects and their importance in structure-based design","volume":"17","author":"Senger","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104675_b0060","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/jm801331y","article-title":"The pKBHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists","volume":"52","author":"Laurence","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0065","doi-asserted-by":"crossref","first-page":"14345","DOI":"10.1002\/chem.201703244","article-title":"Conformational aspects in the design of inhibitors for serine hydroxymethyltransferase (SHMT): biphenyl, aryl sulfonamide, and aryl sulfone motifs","volume":"23","author":"Schwertz","year":"2017","journal-title":"Chem Eur J"},{"key":"10.1016\/j.drudis.2026.104675_b0070","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A medicinal chemist\u2019s guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0075","series-title":"Drug Discovery Cambridge","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1039\/9781849731102-00210","article-title":"Chapter 5. Sulfonamide as an essential functional group in drug design","author":"Kalgutkar","year":"2010"},{"key":"10.1016\/j.drudis.2026.104675_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113399","article-title":"Structure property relationships of N-acylsulfonamides and related bioisosteres","volume":"218","author":"Francisco","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0085","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/cbdd.13043","article-title":"N-acylsulfonamides: synthetic routes and biological potential in medicinal chemistry","volume":"90","author":"Ammazzalorso","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2026.104675_b0090","series-title":"Metabolism, pharmacokinetics and toxicity of functional groups: impact of chemical building blocks on ADMET","author":"Smith","year":"2010"},{"key":"10.1016\/j.drudis.2026.104675_b0095","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1021\/jm000069h","article-title":"N-[[(5-methyl-3-phenylisoxazol-4-Yl)- phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration","volume":"43","author":"Talley","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5937\/savteh1701058T","article-title":"Antimicrobial sulfonamide drugs","volume":"6","author":"Tacic","year":"2017","journal-title":"Adv Technol"},{"key":"10.1016\/j.drudis.2026.104675_b0105","doi-asserted-by":"crossref","first-page":"12290","DOI":"10.1021\/acs.jmedchem.0c00530","article-title":"Amide bond bioisosteres: strategies, synthesis, and successes","volume":"63","author":"Kumari","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0110","series-title":"An introduction to medicinal chemistry","author":"Patrick","year":"2023"},{"key":"10.1016\/j.drudis.2026.104675_b0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/pharmacy7030132","article-title":"Sulfonamide allergies","volume":"7","author":"Giles","year":"2019","journal-title":"Pharmacy"},{"key":"10.1016\/j.drudis.2026.104675_b0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1385\/CRIAI:24:3:229","article-title":"Reactive metabolites and adverse drug reactions: clinical considerations","volume":"24","author":"Knowles","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.drudis.2026.104675_b0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/tx900034r","article-title":"Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation","volume":"22","author":"Callan","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.drudis.2026.104675_b0130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104675_b0135","doi-asserted-by":"crossref","DOI":"10.25259\/AJC_513_2025","article-title":"Sulfonamide derivatives targeting urease: structural diversity and therapeutic potential","volume":"19","author":"Ahmed","year":"2026","journal-title":"Arab J Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0140","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/cmdc.200600155","article-title":"Prediction of ADMET properties","volume":"1","author":"Norinder","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2026.104675_b0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1021368007777","article-title":"Current trends in lead discovery: are we looking for the appropriate properties?","volume":"5","author":"Oprea","year":"2002","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104675_b0150","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/13543784.14.9.1129","article-title":"The therapeutic potential of NS3 protease inhibitors in HCV infection","volume":"14","author":"Goudreau","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2026.104675_b0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbagen.2004.02.008","article-title":"Structure\u2013activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors","volume":"1672","author":"Poliakov","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2026.104675_b0160","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/jm401840s","article-title":"Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection","volume":"57","author":"Scola","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0165","doi-asserted-by":"crossref","first-page":"7184","DOI":"10.1016\/j.bmc.2007.07.027","article-title":"Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs","volume":"15","author":"B\u00e4ck","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0170","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0968-0896(03)00179-2","article-title":"Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase\/NTPase): a comparative study of different C-terminals","volume":"11","author":"Johansson","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0175","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/jm400164c","article-title":"Discovery of danoprevir (ITMN-191\/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3\/4A protease","volume":"57","author":"Jiang","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0180","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/anie.200906696","article-title":"Induced\u2010fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3\/NS4A protease target","volume":"49","author":"Cummings","year":"2010","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drudis.2026.104675_b0185","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s40265-013-0153-9","article-title":"Simeprevir: first global approval","volume":"73","author":"Vaidya","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104675_b0190","doi-asserted-by":"crossref","unstructured":"Kainthla R, Kim KB, Falchook GS. Dabrafenib. In: Martens UM, eds.Small Molecules in Oncology, 2nd ed. Springer. 2014;201:227\u201340.","DOI":"10.1007\/978-3-642-54490-3_14"},{"key":"10.1016\/j.drudis.2026.104675_b0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/med.21404","article-title":"Metastatic melanoma: insights into the evolution of the treatments and future challenges","volume":"37","author":"Millet","year":"2017","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2026.104675_b0200","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.chembiol.2013.06.001","article-title":"Ins and outs of kinase DFG motifs","volume":"20","author":"Treiber","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2026.104675_b0205","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of dabrafenib: a selective inhibitor of raf kinases with antitumor activity against B-raf-Driven tumors","volume":"4","author":"Rheault","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104675_b0210","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2026.104675_b0215","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1527-3458.2002.tb00226.x","article-title":"Almotriptan, a new anti\u2010migraine agent: a review","volume":"8","author":"Gras","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.drudis.2026.104675_b0220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2999(89)90406-8","article-title":"Sumatriptan (GR 43175) interacts selectively with 5-HT m and 5-HT m binding sites","volume":"163","author":"Peroutka","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104675_b0225","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acschemneuro.3c00658","article-title":"Development of 2-aminotetralin-type serotonin 5-HT1 agonists: molecular determinants for selective binding and signaling at 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT1F receptors","volume":"15","author":"McGlynn","year":"2024","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2026.104675_b0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0223-5234(97)84362-0","article-title":"Modeling of the agonist binding site of serotonin human 5HT1A, 5-HT1D\u03b1 and 5HTID\u03b2 receptors","volume":"32","author":"Bremmer","year":"1997","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0235","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1021\/jm00018a016","article-title":"Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties","volume":"38","author":"Martin","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0240","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104675_b0245","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-Yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0250","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0255","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0960-894X(03)00029-5","article-title":"Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates\/sulfamides with isozymes I, II and IV","volume":"13","author":"Casini","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104675_b0260","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/pro.5560070303","article-title":"Structures of murine carbonic anhydrase IV and human carbonic anhydrase I1 complexed with brinzolamide: molecular basis of isozyme-drug discrimination","volume":"7","author":"Stams","year":"1998","journal-title":"Protein Sci"},{"key":"10.1016\/j.drudis.2026.104675_b0265","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.4155\/fmc.14.68","article-title":"Sulfonamides and their isosters as carbonic anhydrase inhibitors","volume":"6","author":"Carta","year":"2014","journal-title":"Future Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0270","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-025-00182-4","article-title":"Mechanistic insights into synergistic effects using coupled PK-PD modeling","volume":"15","author":"Sun","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104675_b0275","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40265-016-0549-4","article-title":"Selexipag: first global approval","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104675_b0280","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"58","author":"Asaki","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1527-3466.2005.tb00167.x","article-title":"The novel antiarrhythmic drug dronedarone: comparison with amiodarone","volume":"23","author":"Kathofer","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.drudis.2026.104675_b0290","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104675_b0295","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1021\/jm101596e","article-title":"Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity","volume":"54","author":"Sleebs","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0300","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1021\/ml300321d","article-title":"The role of the acidity of N-heteroaryl sulfonamides as inhibitors of Bcl-2 family protein\u2013protein interactions","volume":"4","author":"Tour\u00e9","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104675_b0305","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: first global approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104675_b0310","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/009127000204200902","article-title":"A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin","volume":"42","author":"White","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104675_b0315","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104675_b0320","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104675_b0325","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-Yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104675_b0330","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn J Clin Oncol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:23:02Z","timestamp":1785946982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1359644626000802"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104675","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of the sulfonamide motif in medicinal chemistry: exploring the pharmacological landscape of FDA-approved and investigational sulfonamide drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104675"}}